Clinical Trials

LymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

35 enrolled

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Neoplasm Metastasis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02211755 2026-04-20

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

28 enrolled

LymphoidMyeloid

Lymphoma, Myelodysplastic Syndromes, Neoplasms

NCT04996160 2026-04-17

Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

2 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00479128 2026-04-16

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

80 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT01695941 2026-04-13

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

24 enrolled

Lymphoid

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT01861314 2026-04-13

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

Other hematologic neoplasm

15 enrolled

Leukemia, Myeloid, Acute

NCT04722146 2026-04-13

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT03984097 2026-04-09

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

50 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04754945 2026-02-18

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

11 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT05556616 2026-01-29

iinnovate-2

15 enrolled 15 charts

Multiple Myeloma

NCT05137054 2026-01-22

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Phase 1 Recruiting

317 enrolled

Multiple Myeloma

NCT02312102 2026-01-16

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

MyeloidOther hematologic neoplasm

22 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Phase 1 Not yet recruiting

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT04091126 2025-11-28

DREAMM 9

118 enrolled

Multiple Myeloma

NCT03828292 2025-08-19

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

15 enrolled 91 charts

Multiple Myeloma

NCT02783625 2025-06-03

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

114 enrolled

Lymphoid

Lymphoma, Lymphoma, T-Cell

NCT04570631 2025-05-16

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

4 enrolled

Multiple Myeloma

NCT00329589 2025-05-02

A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients

CNSGynecologicHead & Neck

54 enrolled

Brain Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Central Nervous System Neoplasms

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

240 enrolled 2 FDA

Multiple Myeloma

NCT06900647 2025-04-02

BOCIS

Phase 1 Recruiting

20 enrolled

Breast

Breast Neoplasms

NCT01163357 2025-03-26

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Other hematologic neoplasmPlasma cell

18 enrolled

Chromosome 17 deletion, Leukemia, Plasma Cell, Multiple Myeloma

NCT03829020 2024-08-22

Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

9 enrolled

Multiple Myeloma

NCT04956302 2024-06-06

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

1 enrolled

Multiple Myeloma

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04912427 2024-02-09

Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

1 enrolled

Multiple Myeloma

NCT02513186 2024-01-29

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

90 enrolled

Multiple Myeloma

NCT02352558 2023-11-14

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies